Mark Gormley

1.6k total citations
34 papers, 852 citations indexed

About

Mark Gormley is a scholar working on Neurology, Psychiatry and Mental health and Rehabilitation. According to data from OpenAlex, Mark Gormley has authored 34 papers receiving a total of 852 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Neurology, 28 papers in Psychiatry and Mental health and 5 papers in Rehabilitation. Recurrent topics in Mark Gormley's work include Botulinum Toxin and Related Neurological Disorders (28 papers), Cerebral Palsy and Movement Disorders (26 papers) and Neurological disorders and treatments (8 papers). Mark Gormley is often cited by papers focused on Botulinum Toxin and Related Neurological Disorders (28 papers), Cerebral Palsy and Movement Disorders (26 papers) and Neurological disorders and treatments (8 papers). Mark Gormley collaborates with scholars based in United States, France and Australia. Mark Gormley's co-authors include Deborah Gaebler‐Spira, Mauricio R. Delgado, Ann Tilton, Barry S. Russman, H. Kerr Graham, Dennis J. Matthews, Guy Molenaers, Florian Heinen, Pedro Ruiz and Ilona Autti‐Rämö and has published in prestigious journals such as Neurology, PEDIATRICS and Medicine.

In The Last Decade

Mark Gormley

31 papers receiving 804 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Gormley United States 12 702 652 171 125 121 34 852
Francesco Motta Italy 12 611 0.9× 542 0.8× 108 0.6× 124 1.0× 135 1.1× 19 754
Margaret J. Barry United States 10 589 0.8× 530 0.8× 99 0.6× 63 0.5× 182 1.5× 15 819
Barry Rawicki Australia 16 432 0.6× 501 0.8× 202 1.2× 67 0.5× 148 1.2× 30 746
Marcin Bonikowski Poland 10 421 0.6× 398 0.6× 120 0.7× 92 0.7× 71 0.6× 32 510
Cathleen E. Buckon United States 19 388 0.6× 773 1.2× 138 0.8× 108 0.9× 177 1.5× 38 986
Katharine J. Bell United States 12 298 0.4× 663 1.0× 61 0.4× 224 1.8× 142 1.2× 17 834
Catherine Huenaerts Belgium 12 392 0.6× 620 1.0× 209 1.2× 95 0.8× 97 0.8× 36 750
Lucianne Speth Netherlands 12 282 0.4× 456 0.7× 104 0.6× 92 0.7× 152 1.3× 26 557
Charlie Fairhurst United Kingdom 13 278 0.4× 359 0.6× 34 0.2× 84 0.7× 124 1.0× 26 495
Adrienne Fosang Australia 5 332 0.5× 392 0.6× 122 0.7× 69 0.6× 88 0.7× 5 462

Countries citing papers authored by Mark Gormley

Since Specialization
Citations

This map shows the geographic impact of Mark Gormley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Gormley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Gormley more than expected).

Fields of papers citing papers by Mark Gormley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Gormley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Gormley. The network helps show where Mark Gormley may publish in the future.

Co-authorship network of co-authors of Mark Gormley

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Gormley. A scholar is included among the top collaborators of Mark Gormley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Gormley. Mark Gormley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gormley, Mark, Darcy Fehlings, Marcin Bonikowski, et al.. (2024). Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Pediatric Upper and Lower Limb Spasticity: Results From 2 Open-Label, Long-term Extension Trials. Journal of Child Neurology. 40(3). 168–179.
2.
Deshpande, Nikhil, et al.. (2023). Safety of botulinum toxin injections in children less than one year old: A retrospective chart review. Journal of Pediatric Rehabilitation Medicine. 17(1). 67–73.
3.
Dimitrova, Rozalina, Mark Gormley, Darcy Fehlings, et al.. (2021). Efficacy and safety of onabotulinumtoxinA with standardized occupational therapy for treatment of pediatric upper limb spasticity: Phase III placebo-controlled randomized trial. Neurorehabilitation. 49(3). 469–479. 11 indexed citations
4.
Vasdev, Ranveer, et al.. (2020). Litigation risks despite guideline adherence for acute spinal cord injury: time is spine. Neurosurgical FOCUS. 49(5). E17–E17. 2 indexed citations
5.
Dursun, Nigar, Marcin Bonikowski, Edward Dabrowski, et al.. (2019). Efficacy of Repeat AbobotulinumtoxinA (Dysport®) Injections in Improving Gait in Children with Spastic Cerebral Palsy. Developmental Neurorehabilitation. 23(6). 368–374. 11 indexed citations
6.
Dabrowski, Edward, Marcin Bonikowski, Mark Gormley, et al.. (2018). AbobotulinumtoxinA Efficacy and Safety in Children With Equinus Foot Previously Treated With Botulinum Toxin. Pediatric Neurology. 82. 44–49. 4 indexed citations
7.
Tilton, Ann, et al.. (2017). Dysport® (abobotulinumtoxinA) injection in muscles in pediatric patients with lower limb spasticity (P3.207). Neurology. 88(16_supplement). 1 indexed citations
8.
Matthews, Dennis J., Samuel Ignacio Pascual Pascual, Ann Tilton, et al.. (2016). Poster 485 Safety and Tolerability of AbobotulinumtoxinA (Dysport) in Children (2‐17 Years) with Lower Limb Spasticity Due to Cerebral Palsy: A Pooled Analysis of 8 Clinical Trials. PM&R. 8(9S). S318–S318. 2 indexed citations
9.
10.
Brandenburg, Joline E., Linda E. Krach, & Mark Gormley. (2013). Use of Rimabotulinum Toxin for Focal Hypertonicity Management in Children with Cerebral Palsy with Nonresponse to Onabotulinum Toxin. American Journal of Physical Medicine & Rehabilitation. 92(10). 898–904. 6 indexed citations
11.
Gormley, Mark, et al.. (2006). Muscle fiber orientation in muscles commonly injected with botulinum toxin: An anatomical pilot study. Neurotoxicity Research. 9(2-3). 115–120. 22 indexed citations
12.
Gormley, Mark, et al.. (2001). Spasticity management in the child with spastic quadriplegia. European Journal of Neurology. 8(s5). 127–135. 32 indexed citations
13.
Graham, H. Kerr, K. Roger Aoki, Ilona Autti‐Rämö, et al.. (2000). Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait & Posture. 11(1). 67–79. 295 indexed citations
14.
Gormley, Mark. (1999). Management of Spasticity in Children: Part 1: Chemical Denervation. Journal of Head Trauma Rehabilitation. 14(1). 97–99. 3 indexed citations
15.
Gormley, Mark. (1999). Management of Spasticity in Children: Part 2: Oral Medications and Intrathecal Baclofen. Journal of Head Trauma Rehabilitation. 14(2). 207–209. 3 indexed citations
16.
Gormley, Mark. (1999). The treatment of cerebral origin spasticity in children. Neurorehabilitation. 12(2). 93–103. 6 indexed citations
17.
Kriel, Robert L., et al.. (1997). Failure of absorption of baclofen after rectal administration. Pediatric Neurology. 16(4). 351–352. 7 indexed citations
18.
Gormley, Mark, Christopher O’Brien, & Stuart A. Yablon. (1997). A clinical overview of treatment decisions in the management of spasticity. Muscle & Nerve. 20(S6). 14–20. 2 indexed citations
19.
Russman, Barry S., Ann Tilton, & Mark Gormley. (1997). Cerebral palsy: A rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle & Nerve. 20(S6). 181–193. 97 indexed citations
20.
Kriel, Robert L., et al.. (1996). Automatic garage door openers: hazard for children.. PubMed. 98(4 Pt 1). 770–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Motta Breakdown of academic impact, for papers by Margaret J. Barry Breakdown of academic impact, for papers by Barry Rawicki Breakdown of academic impact, for papers by Marcin Bonikowski Breakdown of academic impact, for papers by Cathleen E. Buckon Breakdown of academic impact, for papers by Katharine J. Bell Breakdown of academic impact, for papers by Catherine Huenaerts Breakdown of academic impact, for papers by Lucianne Speth Breakdown of academic impact, for papers by Charlie Fairhurst Breakdown of academic impact, for papers by Adrienne Fosang
Rankless by CCL
2026